“I’m right in the mix,” claimed McIlroy, the world number three, after posting a second round 68 – five birdies and one lone ...

Tarsus Pharmaceuticals is expanding its pipeline to target meibomian gland disease and rosacea, with promising Phase 2 ...

Bob MacIntyre reckoned it was a case of “robbery” as he shot the “best two-under-par round of my life” to be in the mix along ...

IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

Beyond MariTide, Amgen has a rich pipeline with more than 30 phase 3 programs. Some are for existing medicines seeking label ...

Tourism Northern Ireland has described the recent Amgen Irish Open in Co Down as “incredibly successful”. More than 71,000 ...

This Comment is linked to The Lancet Haematology Series on Sexual Health in Patients with Haematological Malignancies; we ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

False Claims Act suit alleging that medical practices engaged in a scheme to overbill Medicare for Amgen Inc. drugs is now dismissed, a New York federal district court said.

In addition to Dr. Bachleda, members of the Eyconis Board of Directors include Dr. Cunningham, who serves as Executive Chair, Jan Mikkelsen, President & CEO of Ascendis Pharma A/S, Daniel Estes, Ph.D.

ALS, MS, post-traumatic brain injury? This biotech company has a target choice to make for an upcoming clinical trial — and ...

Amgen Inc. closed $13.93 short of its 52-week high ($346.85), which the company reached on July 25th.